1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Poxel’s Phase II Data Add AMP Kinase Activation To NASH Possibilities

 
• By Joseph Haas

Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.

businessman chooses the path strategy
Add AMPK activation to the mechanisms of action now in mid-stage NASH development

Poxel SA established itself as a potential impact player in non-alcoholic steatohepatitis on 1 October with Phase IIa data showing its first-in-class AMP kinase activator can significantly reduce liver fat mass in NASH patients, with greater efficacy seen in patients also diagnosed with type 2 diabetes. The drug, PXL770, also demonstrated statistically significant reductions in liver enzymes and hemoglobin A1c levels in the 120-patient study.

Based in Lyon, France, Poxel is focused on novel therapies for metabolic disease. Beyond a pair of mid-stage NASH candidates,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from R&D

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.